UNSPSC 51386003: Bufezolac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C21H22N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PUA774J9MP, chemically known as 1-isobutyl-3,4-diphenylpyrazole-5-acetic acid but generally known as bufezolac, which bears US NIH Compound Identifier 68676. European Medicines Agency schedules Bufezolac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05962MIG.

UNSPSC 51386003 Bufezolac is a Commodity code nominally identifying a single anti-inflammatory pharmaceutical product, but the recent state and local opportunities tagged under it diverge sharply from that narrow scope. The three recent solicitations show state and local governments actually buying under this code to source pharmaceuticals and drug-management systems across a broader landscape: naloxone and drug deactivation equipment for emergency response; direct-to-manufacturer prescription fulfillment arrangements; and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing networks. The issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating jurisdictions). The mismatch between the code name and the actual procurements suggests either miscoding at the state and local level or a broader pharmaceutical family tagged incorrectly to this specific commodity.

Recent activity spans Florida, Texas, and Minnesota with a multistate cooperative footprint. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023—note the source shows a date inconsistency) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, requiring electronic bid submission and E-Verify compliance. The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, designed to inform future formal solicitation strategy. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, released an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with evaluations weighted heavily toward price competitiveness (75 percent), requiring cGMP and Drug Supply Chain Security Act certification, and a two-year initial term with optional extensions.